Merus (NASDAQ:MRUS) Now Covered by The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Merus (NASDAQ:MRUS) in a research note released on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $73.00 target price on the biotechnology company’s stock.

MRUS has been the topic of several other reports. Guggenheim increased their target price on Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Lifesci Capital raised Merus to a “strong-buy” rating in a research report on Monday, July 29th. UBS Group started coverage on Merus in a research report on Thursday, October 24th. They issued a “buy” rating and a $72.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 target price on shares of Merus in a research report on Friday, November 1st. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $67.00 price target on shares of Merus in a report on Thursday, July 25th. One analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $85.45.

Merus Trading Up 0.7 %

Merus stock opened at $44.68 on Thursday. The stock has a market cap of $3.06 billion, a P/E ratio of -11.30 and a beta of 1.12. The stock has a 50 day moving average of $50.49 and a 200-day moving average of $51.81. Merus has a 52 week low of $22.26 and a 52 week high of $61.61.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $11.77 million for the quarter, compared to analyst estimates of $9.11 million. As a group, equities analysts predict that Merus will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MRUS. Wellington Management Group LLP boosted its stake in Merus by 73.6% during the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock valued at $144,260,000 after buying an additional 1,224,573 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in Merus during the first quarter valued at about $53,377,000. Marshall Wace LLP boosted its stake in Merus by 813.3% during the second quarter. Marshall Wace LLP now owns 957,952 shares of the biotechnology company’s stock valued at $56,682,000 after buying an additional 853,060 shares in the last quarter. Logos Global Management LP bought a new position in Merus during the second quarter valued at about $50,294,000. Finally, Novo Holdings A S bought a new position in Merus during the second quarter valued at about $39,940,000. Institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.